Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer) and Iron Sucrose in Subjects With Iron Deficiency Anaemia and Who Are Intolerant or Unresponsive to Oral Iron Therapy or Who Need Iron Rapidly (PROVIDE)

Next Previous
Trial Profile

A Phase III, Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer) and Iron Sucrose in Subjects With Iron Deficiency Anaemia and Who Are Intolerant or Unresponsive to Oral Iron Therapy or Who Need Iron Rapidly (PROVIDE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ferric derisomaltose (Primary) ; Iron sucrose
  • Indications Iron deficiency anaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms PROVIDE
  • Sponsors Pharmacosmos

Most Recent Events

  • 14 Mar 2017 New data from this trial published in the American Journal of Hematology, as reported in a Pharmacosmos Media Release.
  • 14 Mar 2017 Results published in the Pharmacosmos Media Release
  • 19 Aug 2016 Primary endpoint (Proportion of subjects with an Hb increase of ≥2 g/dL from baseline) has been met, according to a Pharmacosmos media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top